Tabakentwöhnung bei COPD^[*]

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (chronic obstructive pulmonary disease, abgekürzt: COPD) ist eine der weltweit führenden Todesursachen. Das Rauchen ist die mit Abstand häufigste Ursache der COPD. Der Verzicht auf Tabakrauchen ist deswegen die effektivste Einzelmaßnahme und zentraler Aspekt der Prävention der COPD. Zum Thema COPD sind mehrere Leitlinien publiziert, die bereits zu Prävention, Diagnostik, Therapie und Rehabilitation Stellung nehmen. Um eine Standardisierung und Etablierung der Tabakentwöhnung flächendeckend in Deutschland zu gewährleisten, wurde im Jahr 2008 aufgrund der Komplexität des Themas eine eigene Leitlinie zur Tabakentwöhnung bei COPD entwickelt. Die vorliegende Fassung ist ein Update dieser Leitlinie Tabakentwöhnung bei COPD unter Berücksichtigung aktueller Erkenntnisse und Forschungsergebnisse. Aufgabe der S3-Leitlinie ist es, die Tabakentwöhnung bei Patienten mit COPD als zentralen Aspekt der Therapie ausführlich und praxisnah abzubilden.

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Cigarette smoking is the main cause of COPD. Quitting smoking is thus the most effective treatment strategy and central in COPD prevention. A number of guidelines on prevention, diagnosis, therapy and rehabilitation of COPD have been published. To help implementing and standardizing smoking cessation in COPD a guideline was published 2008 in Germany focusing on this complex issue. The present guideline is an update of the 2008 guideline and has a high grade of evidence (S3 according to the AWMF; Arbeitsgemeinschaft wissenschaftlicher medizinischer Fachgesellschaften). The guideline gives comprehensive and practical information on how to integrate smoking cessation as an central part of COPD therapy.

Unter Mitwirkung der folgenden Wissenschaftlichen Fachgesellschaften und Institutionen:
Wissenschaftlicher Aktionskreis Tabakentwöhnung (WAT) e. V.
Deutsche Gesellschaft für Psychiatrie
Psychotherapie und Nervenheilkunde (DGPPN)
Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht) e. V.
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin e. V. (DEGAM)
Deutsche Gesellschaft für Innere Medizin e. V. (DGIM)
Bundesverband der Pneumologen (BDP)
Klinische Psychologie der Deutschen Gesellschaft für Psychologie e. V.
Deutsche Atemwegsliga e. V.
Verabschiedet von den Vorständen der beteiligten Fachgesellschaften am 21.12. 2013

• Literatur

• 1 Rodrigez-Roisin R et al. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of COPD (Revised 2011). 2011 Accessed at: http://www.goldcopd.org
• 2 Vogelmeier C, Buhl R, Criée CP et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem 2007 (COPD). Pneumologie 2007; 61: e1-e40
• 3 Abholz HH, Gillissen A, Magnussen H et al. Bundesärztekammer (BÄK). Nationale Versorgungs-Leitlinie COPD, Langfassung, Version 1.2. 2006
• 4 Phillips B, Ball C, Sackett D. Levels of evidence. Oxford: Centre of Evidence-based Medicine; 2001 http://www.cebm.net/index.aspx?o=1025
• 5 Pabst A, Piontek D, Kraus L et al. Substanzkonsum und substanzbezogene Störungen. Sucht 2010; 56: 327-336
• 6 Lampert T. Rauchen – Aktuelle Entwicklungen bei Erwachsenen. GBE kompakt 2(4). Robert Koch-Institut Berlin, Hrsg. 2011 www.rki.de/gbe-kompakt
• 7 Tønnesen P, Carrozzi L, Fagerström KO et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417
• 8 Decramer M, Decramer M. European Respiratory Roadmap Initiative. The European respiratory roadmap. Lancet 2011; 378: 1765-1767
• 9 O'Dell LE. A psychobiological framework of the substrates that mediate nicotine use during adolescence. Neuropharmacology 2009; 56: 263-278
• 10 Markou A. Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3159-3168
• 11 Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905-908
• 12 Corrigall WA, Franklin KB, Coen KM et al. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992; 107: 285-289
• 13 Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009; 78: 756-765
• 14 Le Foll B, Goldberg SR. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology 2006; 184: 367-381
• 15 Piper ME, Schlam TR, Cook JW et al. Tobacco withdrawal components and their relations with cessation success. Psychopharmacology 2011; 216: 569-578
• 16 Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008; 98: 169-178
• 17 Fletcher PJ, Lê AD, Higgins GA. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 2008; 172: 361-383
• 18 Brody AL, Olmstead RE, London ED et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161: 1211-1218
• 19 Takada-Takatori Y, Kume T, Izumi Y et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009; 32: 318-324
• 20 Fidler JA, Wardle J, Brodersen NH et al. Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more. Tobacco control 2006; 15: 205-209
• 21 Fiore MC. Treating tobacco use and dependence. Clinical practice guideline 2008 update. Rockville, MD, USA: US Department of Health and Human Services. Public Health Service;
• 22 WHO. ICD10CM classification of diseases. 2013 http://www.icd10data.com/ICD10CM/Codes/F01-F99/F10-F19/F17-
• 23 Nelson CB, Wittchen HU. Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany. European addiction research 1998; 4: 42-49
• 24 Center for Disease Control and Prevention (CDC). Cigarette smoking among adults--United States, 1995. MMWR Morb Mortal Wkly Rep 1997; 46: 1217-1220
• 25 Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983; 51: 390-395
• 26 West R, Sohal T. “Catastrophic” pathways to smoking cessation: findings from national survey. BMJ 2006; 332: 458-460
• 27 Andreas S, Rittmeyer A. Epidemiologie und Bedeutung tabakassoziierter Lungenkrankheiten. Der Pneumologe 2012; 9: 177-184
• 28 Andreas S, Batra A, Behr J et al. Tabakentwçhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie 2008; 62: 255-272
• 29 Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620
• 30 Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504
• 31 Shahab L, Jarvis MJ, Britton J et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043-1047
• 32 de Marco R, Accordini S, Cerveri I et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125
• 33 Chapman KR, Mannino DM, Soriano JB et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207
• 34 Nowak D, Berger K, Lippert B et al. Epidemiology and health economics of COPD across Europe: a critical analysis. Treatments in respiratory medicine 2005; 4: 381-395
• 35 Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750
• 36 Burney P, Suissa S, Soriano JB et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J 2003; 43: 1s-44s
• 37 Lundbäck B, Lindberg A, Lindström M et al. Not 15 but 50% of smokers develop COPD? --Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122
• 38 Miravitlles M, Soriano JB, García-Río F et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868
• 39 European Commission; Office for Official Publications of the European Communities. Tobacco or Health in the European Union – past, present and future. The ASPECT Consortium. 2004
• 40 Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respiratory care 2003; 48: 1204-1213
• 41 Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 yearsʼ observations on male British doctors. BMJ 2004; 328: 1519
• 42 Løkke A, Lange P, Scharling H et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939
• 43 Parrott S, Godfrey C. Economics of smoking cessation. BMJ 2004; 328: 947-949
• 44 Prescott E, Bjerg AM, Andersen PK et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-827
• 45 Xu X, Li B, Wang LL. Gender difference in smoking effects on adult pulmonary function. The Eur Respir J 1994; 7: 477-483
• 46 Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men?. Clinics in chest medicine 2004; 25: 331-341
• 47 Hunninghake GM, Cho MH, Tesfaigzi Y et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608
• 48 Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367: 1216-1219
• 49 Falk GA, Briscoe WA. Alpha-1-antitrypsin deficiency in chronic obstructive pulmonary disease. Annals of internal medicine 1970; 72: 427-429
• 50 Rabe KF, Beghé B, Luppi F et al. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med 2007; 175: 1222-1232
• 51 Anthonisen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Annals of internal medicine 2005; 142: 233-239
• 52 Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959
• 53 Andreas S, Anker Stefan SD, Scanlon PD et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128: 3618-3624
• 54 Yanbaeva DG, Dentener MA, Creutzberg EC et al. Systemic effects of smoking. Chest 2007; 131: 1557-1566
• 55 Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22: 413-417
• 56 Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535
• 57 Kerstjens HA, Rijcken B, Schouten JP et al. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827
• 58 Fletcher C, Peto R. The natural history of chronic airflow obstruction. British medical journal 1977; 1: 1645-1648
• 59 Gold DR, Wang X, Wypij D et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937
• 60 Sherrill DL, Lebowitz MD, Knudson RJ et al. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991; 144: 17-22
• 61 Xu X, Weiss ST, Rijcken B et al. Smoking, changes in smoking habits, and rate of decline in FEV₁: new insight into gender differences. Eur Respir J 1994; 7: 1056-1061
• 62 Anthonisen NR. Lung Health Study. Am Rev Respir Dis 1989; 140: 871-872
• 63 Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679
• 64 Anthonisen NR, Lindgren PG, Tashkin DP et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005; 26: 45-51
• 65 Scanlon PD, Connett JE, Waller LA et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390
• 66 Kohansal R, Martinez-Camblor P, Agustí A et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10
• 67 Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276
• 68 Magnussen H, Goeckenjan G, Köhler D et al. Guidelines to long-term oxygen therapy. Pneumologie 2001; 55: 454-464
• 69 Lacasse Y, LaForge J, Maltais F. Got a match? Home oxygen therapy in current smokers. Thorax 2006; 61: 374-375
• 70 Yin P, Jiang CQ, Cheng KK et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet 2007; 370: 751-757
• 71 Jaakkola MS, Jaakkola JJ. Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention. Eur Respir J 2006; 28: 397-408
• 72 Ebbert JO, Croghan IT, Schroeder DR et al. Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey. Environ Health 2007; 6: 28
• 73 Heidrich J, Wellmann J, Heuschmann PU et al. Mortality and morbidity from coronary heart disease attributable to passive smoking. European heart journal 2007; 28: 2498-2502
• 74 European Respiratory Society. Lifting the smoke screen – 10 reasons for a smoke free Europe. Brussels: 2006: 28 ff
• 75 Raupach T, Radon K, Nowak D et al. Passive smoking – health consequences and effects of exposure prevention. Pneumologie 2008; 62: 44-50
• 76 Eisner MD, Klein J, Hammond SK et al. Directly measured second hand smoke exposure and asthma health outcomes. Thorax 2005; 60: 814-821
• 77 Lam TH, Ho LM, Hedley AJ et al. Secondhand smoke and respiratory ill health in current smokers. Tobacco control 2005; 14: 307-314
• 78 Eisner MD, Balmes J, Katz PP et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health 2005; 4: 7
• 79 Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554
• 80 Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
• 81 Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703
• 82 Jiménez-Ruiz CA, Masa F, Miravitlles M et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370
• 83 Jiménez-Ruiz C, Miravitlles M, Sobradillo V et al. Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease?. Nicotine Tob Res 2004; 6: 649-653
• 84 von Hertzen L, Reunanen A, Impivaara O et al. Airway obstruction in relation to symptoms in chronic respiratory disease – a nationally representative population study. Respir Med 2000; 94: 356-363
• 85 Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med 2011; 105: 477-484
• 86 Medici TC, Unger S, Rüegger M. Smoking pattern of smokers with and without tobacco-smoke-related lung diseases. Am Rev Respir Dis 1985; 131: 385-388
• 87 Killen JD, Fortmann SP, Kraemer HC et al. Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol 1992; 60: 797-801
• 88 Clark KD, Wardrobe-Wong N, Elliott JJ et al. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur Respir J 1998; 12: 395-399
• 89 van Dijk WD, Heijdra Y, Scheepers PT et al. Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Medical hypotheses 2010; 74: 277-280
• 90 Wagena EJ, van der Meer RM, Ostelo RJ et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815
• 91 Yohannes AM, Roomi J, Baldwin RC et al. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age and ageing 1998; 27: 155-160
• 92 Dudley DL, Glaser EM, Jorgenson BN et al. Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease. 3. Dealing with psychiatric disease (as distinguished from psychosocial or psychophysiologic problems). Chest 1980; 77: 677-684
• 93 Isoaho R, Puolijoki H, Huhti E et al. Chronic obstructive pulmonary disease and self-maintaining functions in the elderly--a population-based study. Scand J Prim Health Care 1995; 13: 122-127
• 94 O'Neill ES. Illness representations and coping of women with chronic obstructive pulmonary disease: a pilot study. Heart & lung 2002; 31: 295-302
• 95 Di Marco F, Verga M, Reggente M et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med 2006; 100: 1767-1774
• 96 Webb RT, Kontopantelis E, Doran T et al. Suicide risk in primary care patients with major physical diseases: a case-control study. Arch Gen Psychiatry 2012; 69: 256-264
• 97 Ng TP, Niti M, Tan WC et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67
• 98 Vogl M, Wenig CM, Leidl R et al. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC public health 2012; 12: 203
• 99 Khaled SM, Bulloch AG, Williams JV et al. Persistent heavy smoking as risk factor for major depression (MD) incidence – evidence from a longitudinal Canadian cohort of the National Population Health Survey. Journal of psychiatric research 2012; 46: 436-443
• 100 Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane database of systematic reviews 2004; 4: CD000031
• 101 Breslau N, Johnson EO, Hiripi E et al. Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Archives of general psychiatry 2001; 58: 810-816
• 102 Glassman AH, Covey LS, Stetner F et al. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929-1932
• 103 Dierker LC, Avenevoli S, Stolar M et al. Smoking and depression: an examination of mechanisms of comorbidity. The American journal of psychiatry 2002; 159: 947-953
• 104 Covey LS, Glassman AH, Stetner F. Cigarette smoking and major depression. Journal of addictive diseases 1998; 17: 35-46
• 105 Fortes C, Mastroeni S, Alessandra S et al. The combination of depressive symptoms and smoking shorten life expectancy among the aged. Int Psychogeriatr 2011; 1-7
• 106 Chaiton MO, Cohen JE, O'Loughlin J et al. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC public health 2009; 9: 356
• 107 Goodwin RD, Lavoie KL, Lemeshow AR et al. Depression, Anxiety, and COPD: The Unexamined Role of Nicotine Dependence. Nicotine & tobacco research 2011; 14: 176-183
• 108 Wilhelm K, Arnold K, Niven H et al. Grey lungs and blue moods: smoking cessation in the context of lifetime depression history. The Australian and New Zealand journal of psychiatry 2004; 38: 896-905
• 109 Batra A, Lindinger P, Schütz C. Tabakbedingte Störungen „Leitlinie Tabakentwöhnung“. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. 2004
• 110 Heatherton TF, Kozlowski LT, Frecker RC et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British journal of addiction 1991; 86: 1119-1127
• 111 Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012; 14: 75-78
• 112 Anda RF, Williamson DF, Escobedo LG et al. Depression and the dynamics of smoking. A national perspective. JAMA 1990; 264: 1541-1545
• 113 Killen JD, Fortmann SP, Kraemer HC et al. Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. J Consult Clin Psychol 1996; 64: 1060-1067
• 114 Löwe B. PHQ-D – Gesundheitsfragebogen für Patienten. In: Schumacher J, Strauss B, eds. Klinische Interviews und Ratingskalen Göttingen. Hogrefe; 2004
• 115 Bakker IM, Terluin B, van Marwijk HW et al. Test-retest reliability of the PRIME-MD: limitations in diagnosing mental disorders in primary care. European journal of public health 2009; 19: 303-307
• 116 Gräfe K, Zipfel S, Herzog W et al. Screening psychischer Störungen mit dem „Gesundheitsfragebogen für Patienten (PHQ-D)“. Diagnostica 2004; 50: 171-181
• 117 Gilbody S, Richards D, Barkham M. Diagnosing depression in primary care using self-completed instruments: UK validation of PHQ-9 and CORE-OM. Br J Gen Pract 2007; 57: 650-652
• 118 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-1744
• 119 Riemann K, Gerber U. Standardisierung von Fragestellungen zum Rauchen: ein Beitrag zur Qualitätssicherung in der Präventionsforschung. 4. ed. Köln: BZgA. Bundeszentrale für gesundheitliche Aufklärung; 2000
• 120 Deutsche Krebshilfe & Deutsches Krebsforschungszentrum. 190; Quelle Rauchtertagebuch: Broschüre „Endlich Aufatmen“. 2010
• 121 West R, Hajek P, Stead L et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303
• 122 Hilberink SR, Jacobs JE, Schlösser M et al. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ Couns 2006; 61: 449-457
• 123 West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999
• 124 Humerfelt S, Eide GE, Kvåle G et al. Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV1 and asbestos exposure. Eur Respir J 1998; 11: 284-290
• 125 Bize R, Burnand B, Mueller Y et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane database of systematic reviews 2005; 4: CD004705
• 126 A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283: 3244-3254
• 127 Soria R, Legido A, Escolano C et al. A randomised controlled trial of motivational interviewing for smoking cessation. Br J Gen Pract 2006; 56: 768-774
• 128 Miller WR. Motivational interviewing: research, practice, and puzzles. Addictive behaviors 1996; 21: 835-842
• 129 Lai DT, Cahill K, Qin Y et al. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010; 1: CD006936
• 130 Chronic obstructive pulmonary disease, National institute for clinical excellence. www.nice.org.uk/CG012NICEguideline
• 131 Kotz D, Wesseling G, Aveyard P et al. Smoking cessation and development of respiratory health in smokers screened with normal spirometry. Respir Med 2011; 105: 243-249
• 132 Kotz D, Wesseling G, Huibers MJ et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33: 754-762
• 133 Parkes G, Greenhalgh T, Griffin M et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336: 598-600
• 134 Sundblad BM, Larsson K, Nathell L. Lung function testing influences the attitude toward smoking cessation. Nicotine & tobacco research 2010; 12: 37-42
• 135 van der Aalst CM, van den Bergh KA, Willemsen MC et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010; 65: 600-605
• 136 van der Aalst CM, van Klaveren RJ, van den Bergh KAM et al. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J 2011; 37: 1466-1473
• 137 OʼHara P, Grill J, Rigdon MA et al. Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive medicine 1993; 22: 304-315
• 138 Willemse BW, Postma DS, Timens W et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476
• 139 Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-505
• 140 Godtfredsen NS, Vestbo J, Osler M et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002; 57: 967-972
• 141 Polednak AP. Trends in mortality from COPD in selected U.S. States differing in tobacco control efforts. COPD 2010; 7: 63-69
• 142 Kanner RE, Anthonisen NR, Connett JE et al. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364
• 143 Au DH, Bryson CL, Chien JW et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. Journal of general internal medicine 2009; 24: 457-463
• 144 Etter JF. Short-term change in self-reported COPD symptoms after smoking cessation in an internet sample. Eur Respir J 2010; 35: 1249-1255
• 145 Willemse BW, ten Hacken NH, Rutgers B et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004; 24: 391-396
• 146 Williamson DF, Madans J, Anda RF et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991; 324: 739-745
• 147 Flegal KM, Troiano RP, Pamuk ER et al. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333: 1165-1170
• 148 Carroll ME, Meisch RA. Increased drug-reinforced behaviour due to food deprivation. In: Thompson T, Dews PB, Je B, eds. Advances in Behavioural Pharmacology. Orlando: Academic Press Inc; 1984
• 149 Pisinger C, Jorgensen T. Weight concerns and smoking in a general population: the Inter99 study. Preventive medicine 2007; 44: 283-289
• 150 Nordstrom BL, Kinnunen T, Utman CH et al. Long-term effects of nicotine gum on weight gain after smoking cessation. Nicotine & tobacco research 1999; 1: 259-268
• 151 Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Annals of internal medicine 2001; 135: 423-433
• 152 Marcus BH, Albrecht AE, King TK et al. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med 1999; 159: 1229-1234
• 153 Kadowaki T, Watanabe M, Okayama A et al. Continuation of smoking cessation and following weight change after intervention in a healthy population with high smoking prevalence. Journal of occupational health 2006; 48: 402-406
• 154 Hughes JR, Gust SW, Skoog K et al. Symptoms of tobacco withdrawal. A replication and extension. Archives of general psychiatry 1991; 48: 52-59
• 155 Strassmann R, Bausch B, Spaar A et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34: 634-640
• 156 Simmons MS, Connett JE, Nides MA et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J 2005; 25: 1011-1017
• 157 Raupach T, Nowak D, Hering T et al. Smoking and pulmonary diseases, positive effects of smoking cessation. Pneumologie 2007; 61: 11-14
• 158 Wagena EJ, Zeegers MP, van Schayck CP et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26: 381-403
• 159 van der Meer RM, Wagena EJ, Ostelo RW et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2003; 2: CD002999
• 160 Bednarek M, Gorecka D, Wielgomas J et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873
• 161 Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract 2002; 52: 132-134
• 162 Anthonisen NR, Connett JE, Enright PL et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339
• 163 Sundblad BM, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res 2008; 10: 883-890
• 164 Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-342
• 165 Wagena EJ, Knipschild PG, Huibers MJ et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 2286-2292
• 166 Norrhall MF, Nilsfelt A, Varas E et al. A feasible lifestyle program for early intervention in patients with chronic obstructive pulmonary disease (COPD): a pilot study in primary care. Primary care respiratory journal 2009; 18: 306-312
• 167 Wilson JS, Fitzsimons D, Bradbury I et al. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. Int J Nurs Stud 2008; 45: 508-517
• 168 Godtfredsen NS, Lam TH, Hansel TT et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008; 32: 844-853
• 169 Christenhusz L, Pieterse M, Seydel E et al. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Couns 2007; 66: 162-166
• 170 http://www.anbieter-raucherberatung.de/suche.php
• 171 Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575
• 172 Hering T, Bölcskei P, Storz C et al. Strukturierte Raucherberatung und Tabakentwöhnung - Tabakentwöhnung in der Praxis-Sprechstunde (das Tabakentwöhnungskonzept des Bundesverbandes der Pneumologen in Deutschland - BDP). In: Haustein K, ed. Vorträge der 5. Deutschen Nikotin Konferenz. Erfurt: Deutsche Gesellschaft für Nikotinforschung; 2002
• 173 Moher M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane database of systematic reviews 2005; 2: CD003440
• 174 Paone G, Serpilli M, Girardi E et al. The combination of a smoking cessation programme with rehabilitation increases stop-smoking rate. J Rehabil Med 2008; 40: 672-677
• 175 West R, Zatonski W, Cedzynska M et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-1200
• 176 Vardavas CI, Anagnostopoulos N, Kougias M et al. Acute pulmonary effects of using an e-cigarette: impact on respiratory flow resistance, impedance and exhaled nitric oxide. Chest 2012; 141: 1400-1406
• 177 Jiménez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A et al. Characteristics of COPD Smokers and Effectiveness and Safety of Smoking Cessation Medications. Nicotine Tob Res 2012; 14: 1035-1039
• 178 Stead LF, Perera R, Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; 1: CD000146
• 179 Organization WH. Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen: Regional Office for Europe; 2001
• 180 Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane database of systematic reviews 2004; 3: CD000146
• 181 Tashkin DP, Rennard S, Hays JT et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599
• 182 Gonzales D, Rennard SI, Nides M et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55
• 183 Nides M, Oncken C, Gonzales D et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561-1568
• 184 Oncken C, Gonzales D, Nides M et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-1577
• 185 Tonstad S, Tønnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71
• 186 Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63
• 187 Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane database of systematic reviews 2011; 2: CD006103
• 188 Mills EJ, Wu P, Lockhart I et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med 2012; 44: 588-5897
• 189 Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PloS one 2010; 5: e15337
• 190 Singh S, Loke YK, Spangler JG et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183: 1359-1366
• 191 Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 04.05.2012; 344: e2856
• 192 Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?. Int J Biochem Cell Biol 2009; 41: 2098-2108
• 193 Paterson NE. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 2009; 603: 1-11
• 194 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007; 1: CD000031
• 195 Bundeszentrale für gesundheitliche Aufklärung (BzgA). Kriterien guter Praxis in der Gesundheitsförderung bei sozial Benachteiligten. 2005
• 196 Morgan WJ. Maternal smoking and infant lung function. Further evidence for an in utero effect. Am J Respir Crit Care Med 1998; 158: 689-690
• 197 Criée CP, Novak D. Einsparpotential durch Prävention bei COPD. In: Schauder P, Berthold H, Eckel H, et al., eds. Zukunft sichern. Senkung der Zahl chronisch Kranker. Verwirklichung einer realistischen Utopie. Deutscher Ärzteverlag; 2006
• 198 Ruff LK, Volmer T, Nowak D et al. The economic impact of smoking in Germany. Eur Respir J 2000; 16: 385-390
• 199 Menn P, Heinrich J, Huber RM et al. Direct medical costs of COPD – an excess cost approach based on two population-based studies. Respir Med 2012; 106: 540-548
• 200 Koskenvuo K, Broms U, Korhonen T et al. Smoking strongly predicts disability retirement due to COPD: the Finnish Twin Cohort Study. Eur Respir J 2011; 37: 26-31
• 201 Murray RP, Connett JE, Rand CS et al. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Preventive medicine 2002; 35: 314-319
• 202 Felten D, Raupach T, Sessler C et al. Efficacy of a cognitive-behavioral program with pharmacological support to achieve smoking cessation. Dtsch Med Wochenschr 2006; 131: 197-202
• 203 Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk analysis 1995; 15: 369-390
• 204 Lock K, Wilson K, Murphy D et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011; 172: 2613-2626
• 205 Lang K. Berechnung der Kosteneffektivität der Nikotinersatztherapie bei Patienten mit chronisch obstruktiver Lungenerkrankung. 2009 http://duepublico.uni-duisburg-essen.de/servlets/DerivateServlet/Derivate-23374/Dissertation_KL.pdf
• 206 Hoogendoorn M, Feenstra TL, Hoogenveen RT et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010; 65: 711-718
• 207 Lewis K, Stern M. British Thoracic Society Recommendations for Hospital Smoking Cessation Services for Commissioners and Health Care Professionals. British Thoracic Society Reports 2012; 4 ISSN ISSN: 2040-2023
• 208 Kim DK, Hersh CP, Washko GR et al. Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res 2011; 12: 1-11
• 209 Pisinger C, Godtfredsen NS, Jørgensen T. Smoking reduction and cessation reduce chronic cough in a general population: the Inter99 study. Clin Respir J 2008; 2: 41-46
• 210 Lapperre TS, Sont JK, van Schadewijk A et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res 2007; 8: 85
• 211 Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res 2007; 9: 631-646
• 212 Hilberink SR, Jacobs JE, Breteler MH et al. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Educ Couns 2011; 83: 120-124
• 213 Toljamo T, Kaukonen M, Nieminen P et al. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care 2010; 28: 41-46
• 214 Schook RM, Postmus BB, van den Berg RM et al. The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteers. J Thorac Oncol 2010; 5: 1240-1245
• 215 Bize R, Burnand B, Mueller Y et al. Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tobacco control 2007; 16: 151-156
• 216 Carpenter MJ, Strange C, Jones Y et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007; 33: 22-28
• 217 Taylor KL, Cox LS, Zincke N et al. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer 2007; 56: 125-134